427 related articles for article (PubMed ID: 11720475)
1. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
Schuyer M; van der Burg ME; Henzen-Logmans SC; Fieret JH; Klijn JG; Look MP; Foekens JA; Stoter G; Berns EM
Br J Cancer; 2001 Nov; 85(9):1359-67. PubMed ID: 11720475
[TBL] [Abstract][Full Text] [Related]
2. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma.
Santini D; Tonini G; Vecchio FM; Borzomati D; Vincenzi B; Valeri S; Antinori A; Castri F; Coppola R; Magistrelli P; Nuzzo G; Picciocchi A
J Clin Pathol; 2005 Feb; 58(2):159-65. PubMed ID: 15677536
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy.
Wootipoom V; Lekhyananda N; Phungrassami T; Boonyaphiphat P; Thongsuksai P
Gynecol Oncol; 2004 Sep; 94(3):636-42. PubMed ID: 15350352
[TBL] [Abstract][Full Text] [Related]
5. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer.
Marx D; Binder C; Meden H; Lenthe T; Ziemek T; Hiddemann T; Kuhn W; Schauer A
Anticancer Res; 1997; 17(3C):2233-40. PubMed ID: 9216694
[TBL] [Abstract][Full Text] [Related]
7. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
[TBL] [Abstract][Full Text] [Related]
12. High bad and bcl-xL gene expression and combined bad, bcl-xL, bax and bcl-2 mRNA levels: molecular predictors for survival of stage 2 soft tissue sarcoma patients.
Köhler T; Würl P; Meye A; Lautenschläger C; Bartel F; Borchert S; Bache M; Schmidt H; Holzhausen HJ; Taubert H
Anticancer Res; 2002; 22(3):1553-9. PubMed ID: 12168836
[TBL] [Abstract][Full Text] [Related]
13. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
15. BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma.
Gonzalez-Campora R; Davalos-Casanova G; Beato-Moreno A; Garcia-Escudero A; Pareja Megia MJ; Montironi R; Lopez-Beltran A
Cancer Lett; 2007 Jun; 250(2):292-9. PubMed ID: 17126995
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas.
Kato K; Kawashiri S; Yoshizawa K; Kitahara H; Yamamoto E
J Oral Pathol Med; 2008 Jul; 37(6):364-71. PubMed ID: 18410312
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis in epithelial ovarian tumours Prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax).
de la Torre FJ; García A; Gil-Moreno A; Planaguma J; Reventos J; Ramón y Cajal S; Xercavins J
Eur J Obstet Gynecol Reprod Biol; 2007 Jan; 130(1):121-8. PubMed ID: 16876311
[TBL] [Abstract][Full Text] [Related]
18. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities.
Sarbia M; Stahl M; Fink U; Willers R; Seeber S; Gabbert HE
Clin Cancer Res; 1998 Dec; 4(12):2991-7. PubMed ID: 9865911
[TBL] [Abstract][Full Text] [Related]
19. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.
Krajewski S; Blomqvist C; Franssila K; Krajewska M; Wasenius VM; Niskanen E; Nordling S; Reed JC
Cancer Res; 1995 Oct; 55(19):4471-8. PubMed ID: 7671262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]